Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriAdeno Vaccine
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TriAdeno Vaccine is an investigational therapeutic cancer vaccine developed by the National Cancer Institute (NCI). It utilizes a viral vector platform consisting of three separate adenovirus type 5 (Ad5) vectors, each engineered to express a specific tumor-associated antigen: Carcinoembryonic Antigen (CEA), Brachyury, and Mucin 1 (MUC1). These antigens are frequently overexpressed in various solid tumors, including colorectal cancer. The vaccine is designed to stimulate the patient's immune system, specifically inducing a T-cell response against tumor cells harboring these proteins. In clinical settings, such as the STAR15 trial, it is being evaluated as part of a multi-agent immunotherapy regimen (including retifanlimab, N-803, and SX-682) for the treatment of metastatic colorectal cancer (mCRC).
- Other names
- CEA/Brachyury/MUC1 TriAdeno VaccineTherapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
02
Targets
MUC1 (Mucin-1 Antigen)T (Brachyury transcription factor)
Beyond the preview
Go deeper on TriAdeno Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriAdeno Vaccine.